About This Episode

We’ll review a case involving a 27-year-old male with high myopia who achieved outstanding visual results following this innovative procedure. Due to his severe refractive error, long axial length, and clear crystalline lenses, traditional treatments such as LASIK, PRK, or Refractive Lens Exchange were contraindicated because of the elevated risks of corneal ectasia or retinal detachment.

The EVO ICL offered the ideal solution — correcting vision without removing natural tissue. Its advanced design features a central port, eliminating the need for a peripheral iridotomy and reducing the risk of elevated intraocular pressure or glaucoma.

Following implantation, the patient experienced a dramatic improvement in visual acuity and quality of life.

We’ll also highlight ten key facts about ICL technology — including its reversibility, biocompatibility, and ability to correct high degrees of myopia and astigmatism regardless of corneal thickness or shape.

Join us as we explore how the EVO ICL continues to redefine refractive surgery — offering patients a safe, effective, and tissue-preserving alternative to laser-based vision correction.